Navigation Links
Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
Date:11/30/2011

CORAL SPRINGS, Fla., Nov. 30, 2011 /PRNewswire/ -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain. The paper was co-authored by Paul Reid, PhD - the Chief Executive Officer of Nutra Pharma's wholly-owned subsidiary, ReceptoPharm and is available ahead of print on the journal's website or through the link: http://tinyurl.com/painmechanism.

"We are pleased to see continuing publications on the uses of cobra venom and cobra venom components," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "This paper explains one of the proposed mechanisms involved in the relief of pain that we've seen with our venom-based therapeutics, Cobroxin and Nyloxin," he concluded.

Nutra Pharma currently produces three drugs for the treatment of pain: Cobroxin®, an over-the-counter pain reliever designed to treat moderate to severe (Stage 2) chronic pain; as well as Nyloxin™ and Nyloxin™ Extra Strength, stronger versions of Cobroxin®. These products are currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress.

"Most of the published research conducted on the use of cobra venom as an analgesic took place decades ago," commented Dr. Paul Reid, CEO of ReceptoPharm. "We have been working diligently to bring the research up to date. While it is well-known that peptides from cobra venom could be used for the treatment of pain and inflammation, the mechanism has not been well-defined. The research in this paper provides a growing understanding of the mechanism of action in pain relief by Alpha-Cobratoxin," he concluded.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The publication of this article should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


'/>"/>
SOURCE Nutra Pharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Nutra Pharma CEO Interviewed by Wall Street Reporter
2. Functional Nutriments Awarded Federal Grant to Apply Its Dog Nutraceutical Research to Human Cancer
3. Nutrastar International Inc. Announces Record Second Quarter 2010 Results
4. Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing
5. 2nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More
6. Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products
7. WellGen Recognized as Nutraceutical “Innovator” by Global Business Insights
8. Henk Hoogenkamp, Accomplished Author and Food Ingredient Scientist, Joins NutraCea as Executive Advisor on the Utilization of Stabilized Rice Bran in Food Ingredient Applications
9. Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health
10. Reuters Highlights NutraPharma Financial Giant Predicts NutraPharma (OTCBB: NPHC) Shares Likely to Outperform the Market
11. Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or ... is excited to announce the formation of EyGen, ... preclinical ophthalmology assets through proof of concept. EyGen,s ... by Portage Pharmaceuticals Limited and being developed for ... and anterior segment diseases. This agent has the ...
(Date:11/30/2016)... Nov. 30, 2016  Tempus, a technology company ... and Penn,s Abramson Cancer Center have partnered to ... response to immunotherapy treatment based on next generation ... part of a research collaboration, Tempus will provide ... cancer patient data to Penn. Utilizing next-generation sequencing, ...
(Date:11/30/2016)... Mass. , Nov. 30, 2016   Merck ... that it has entered into a set of agreements ... services for Merck,s collection of genetic reagents such as ... with Evotec,s screening expertise offers an accelerated pathway to ... discovery starts with the identification of new targets, a ...
(Date:11/30/2016)... Research Triangle Park, North Carolina (PRWEB) , ... November 30, 2016 ... ... Chemistry (IUPAC) approved the names and symbols for four elements: nihonium (Nh), moscovium ... , Following a 5-month period of public review, the names earlier proposed by the ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):